Literature DB >> 16483626

Adenovirus types 11p and 35 attach to and infect primary lymphocytes and monocytes, but hexon expression in T-cells requires prior activation.

Anna Segerman1, Kristina Lindman, Ya-Fang Mei, Annika Allard, Göran Wadell.   

Abstract

Hematopoietic cells are attractive targets for gene therapy, but the conventional adenovirus (Ad) vectors, based on Ad5, transduce these cells inefficiently. One reason for low permissiveness of hematopoietic cells to infection by species C Ads appears to be inefficient attachment. Vectors pseudotyped with species B fibers are clearly more efficient at transducing hematopoietic cells than Ad5. To evaluate which Ad species B type(s) would be the most efficient vector(s) for primary T-cells, B-cells and monocytes, attachment to and entry of the species B1 serotypes 3p and 7p and the species B2 serotypes 11p and 35 into primary PBMCs was studied. Ad11p and Ad35 were the only serotypes to show efficient binding and for which uptake by PBMCs could be detected. Infection of PBMCs by Ad5, Ad11p and Ad35 was compared. Expression of Ad hexons was detected in stimulated PBMCs, most frequently in T-cells, and in unstimulated monocytes, although B-cells appear to be refractory to productive infection. Replication of Ad DNA was severely restricted in most PBMCs. Neither hexon expression nor genome replication could be detected in unstimulated lymphocytes, but FISH and a real-time PCR-based assay suggested that Ad11p and Ad35 DNA reach the nucleus. Activation thus appears to be required for T-cells to be permissive to Ad gene expression. In summary, there are substantial differences between Ad3p and Ad7p on the one hand and Ad11p and Ad35 on the other, in their ability to interact with PBMCs. Ad11p and Ad35 probably represent vectors of choice for these cell types.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16483626     DOI: 10.1016/j.virol.2005.12.044

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells.

Authors:  Sebastian Tuve; Hongjie Wang; Carol Ware; Ying Liu; Anuj Gaggar; Kathrin Bernt; Dmitry Shayakhmetov; Zongyi Li; Robert Strauss; Daniel Stone; André Lieber
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

2.  Species D adenoviruses as oncolytics against B-cell cancers.

Authors:  Christopher Y Chen; Julien S Senac; Eric A Weaver; Shannon M May; Diane F Jelinek; Philip Greipp; Thomas Witzig; Michael A Barry
Journal:  Clin Cancer Res       Date:  2011-09-02       Impact factor: 12.531

3.  Adenoviruses use lactoferrin as a bridge for CAR-independent binding to and infection of epithelial cells.

Authors:  Cecilia Johansson; Mari Jonsson; Marko Marttila; David Persson; Xiao-Long Fan; Johan Skog; Lars Frängsmyr; Göran Wadell; Niklas Arnberg
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

4.  An Efficient Method for the Delivery of the Interleukin-2 Gene to Human Hematopoietic Cells using the 
Fiber-Modified Recombinant Adenovirus.

Authors:  V N Rogozhin; D Yu Logunov; D V Shchebliakov; M M Shmarov; E E Khodunova; I V Galtseva; R V Belousova; B S Naroditsky; A L Gintsburg
Journal:  Acta Naturae       Date:  2011-07       Impact factor: 1.845

5.  Interleukin-24 enhancing antitumor activity of chimeric oncolytic adenovirus for treating acute promyelocytic leukemia cell.

Authors:  Li Liu; Jiabin Ma; Lanyi Qin; Xiaogang Shi; Hongqiang Si; Yahui Wei
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

6.  Bovine Adenovirus-3 Tropism for Bovine Leukocyte Sub-Populations.

Authors:  Sugandhika Khosa; Maria Bravo Araya; Philip Griebel; Natasa Arsic; Suresh K Tikoo
Journal:  Viruses       Date:  2020-12-12       Impact factor: 5.048

7.  Presence of adenovirus species C in infiltrating lymphocytes of human sarcoma.

Authors:  Karin Kosulin; Franziska Hoffmann; Till Sebastian Clauditz; Waldemar Wilczak; Thomas Dobner
Journal:  PLoS One       Date:  2013-05-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.